NCT04492787View on ClinicalTrials.gov

Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

July 6, 2020

Primary Completion Date

April 21, 2022

Study Completion Date

April 21, 2022

Conditions
Irritable Bowel Syndrome with Diarrhea
Interventions
DRUG

Changkang Granule

Take Changkang granule before meals twice a day , one bag for each time

DRUG

Changkang Placebo Granule

Take Changkang Placebo granule before meals twice a day , one bag for each time

Trial Locations (8)

Unknown

Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing

Shengjing Hospital of China Medical University, Dalian

Gansu Provincial Hospital of TCM, Gansu

The first affiliated Hospital of Hunan University of Traditional Chinese Medicine, Hunan

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai

West China Hospital of Sichuan University, Sichuan

Wenzhou Hospital of Traditional Chinese Medicine, Wenzhou

Xiamen Hospital of Traditional Chinese Medicine, Xiamen

All Listed Sponsors
lead

Tasly Pharmaceutical Group Co., Ltd

INDUSTRY

NCT04492787 - Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) | Biotech Hunter | Biotech Hunter